Table 1

Patients’ clinical and laboratory features

Patients, N30
Gender, female, n (%)27 (90%)
Age at evaluation, mean (SD), years59.8 years (SD 13.2 years)
Disease duration, mean (SD), years13.3 years (SD 15.2 years)
Fulfilment of ACR-EULAR classification criteria for pSS, n/N (%)23/30 (76.6%)
Parotid gland enlargement, n/N (%)22/30 (73.3%)
 Chronic (≥12 months)11/22
 Parotid enlargement of long duration (2–11 months)8/22
 Parotid enlargement of short duration (<2 months)3/22
Submandibular gland enlargement, n/N (%)8/30 (26.7%)
 Chronic (≥12 months)5/8
 Submandibular enlargement of long duration (2–11 months)3/8
 Submandibular enlargement of short duration (<2 months)0
Duration of parotid and/or submandibular swelling at the time of biopsy, median (25–75 quartiles), months12 (4.25–14.75)
Anti-Ro/SSA or anti-La/SSB positive, n/N (%)24/30 (80%)
Lymphadenopathy, n/N (%)11/30 (36.67%)
Cryoglobulinemia, n/N (%)5/30 (16.67%)
Cryoglobulinaemic vasculitis, n/N (%)4/30 (13.3%)
Serum monoclonal component, n/N (%)12/30 (40%)
Rheumatoid factor positive, n/N (%)22/30 (73.3%)
Leucopenia (WBC<4.0x109/L, n/N (%)10/30 (33.3%)
Low C4, n/N (%)13/30 (43,3%)
  • ACR, American College of Rheumatology; pSS, primary Sjögren Syndrome; WBC, white blood cells.